PET CT Practice Cases - Radiology Course - Medality / MRI Online

Upcoming Events

PET CT Practice Cases

Content Reviewed: September 1, 2023

Fellowship Cases

Practice Cases are available for purchase in Medality's Fellowship Certificate™ Programs

Fellowship Certificate™ programs are designed to help you become a faster, more confident reader in a subspecialty area. Practice on real-world cases, read alongside the experts, view Gold Standard Reports, and earn CME all on your own schedule. Available for purchase, prices vary.

Purchased separately. Learn More.

Log In Learn More

28.25 CME

27 DICOM Case Files

30 Videos

25 Practice Reports

25 Quiz Questions

3 hr. 13 min.

Course Description

Welcome to the PET CT Practice Cases course!

In this course, you’ll be presented with a series of worklists, comprised of high-yield cases selected by top radiology experts for you to practice your interpretation and reporting skills.

You must complete all topics in this course to receive your Fellowship Certificate. Access Full Fellowship Certificate Program Here

This Practice Cases Course includes:

Practice cases - work through each case in our simulated case review module. Review the DICOM file(s) in our cloud-based viewer, write or dictate your report, answer the quiz question(s), and then compare your report to a gold standard report written by expert faculty.

Review topics - review faculty instructional materials, including expert case review videos, case discussions, key images, and references.

With each practice case question you complete, you’ll receive an updated PET CT Mastery Score to monitor your ongoing performance improvement.

Once you complete all topics in this course, return to the Fellowship Certificate Program page here to claim your Certificate of Completion.

Contact us at support@medality.com with any questions or feedback about the program.

Welcome to the PET CT Practice Cases course!

In this course, you’ll be presented with a series of worklists, comprised of high-yield cases selected by top radiology experts for you to practice your interpretation and reporting skills.

Faculty

Riham El Khouli, MD

Associate Professor of Radiology, Chief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics

University of Kentucky

Michael F. Shriver, MD

Director of Nuclear Medicine

Proscan-NCH Imaging

0 / 5 Cases

Worklist 1

PET Image Viewing Tips for Ambra

Ambra SUV Measurement Demonstration

Ambra PET MIP Demonstration

Ambra Link Fused PET CT with CT Scroll Demonstration

Ambra MPR on Fused PET CT Demonstration

1-1

Weight loss, unintended. Progressive cognitive decline, diplopia, lack of sleep, and possible seizures. Low NMDAR titers in CSF per the electronic medical record. Evaluation for treatment planning. A PET CT was ordered using the FDG tracer.

1-2

History of HIV. Most recent CT chest short interval increase in size of a right lower lobe pulmonary nodule. PET/CT is performed for metabolic characterization of this enlarging pulmonary nodule. A PET CT was ordered using the FDG tracer.

1-3

Female recently diagnosed with small cell lung cancer presenting for initial staging and treatment planning. A PET CT was ordered using the FDG tracer.

1-4

Female with history of stage IB NSCLC status post VATS left lower lobectomy in 2020. Also, history of atypical ductal hyperplasia of the left breast status post left breast excisional biopsy in 2006 and history of CACG with plateau iris syndrome (anomalous large ciliary processes). Concern for recurrent lung cancer on imaging. PET/CT for restaging and subsequent treatment planning. A PET CT was ordered using the FDG tracer.

1-5

18-year-old male presented with a large mediastinal mass, status right VATS with mediastinal mass biopsy revealing diffuse large B-cell lymphoma. PET/CT performed for initial staging and treatment planning. A PET CT was ordered using the FDG tracer.

0 / 5 Cases

Worklist 2

2-1

Female with history of progressive cervical lymphadenopathy has grown in size over 4 weeks prior to presentation to humeral clinic. Excisional cervical lymph node biopsy was performed showing mixed lymphocytic population which may be seen in Hodgkin lymphoma. A PET CT was ordered using the FDG tracer.

2-2

Female with history of nodular sclerosing Hodgkin lymphoma, status post 2 cycles of ABVD, presenting for mid-treatment response assessment. A PET CT was ordered using the FDG tracer.

2-3

A 57-year-old male was recently diagnosed with right tonsillar invasive squamous cell carcinoma; P16 positive. He presents for staging and initial treatment planning. A PET CT was ordered using an FDG tracer.

2-4

Male recently diagnosed with metastatic HPV positive squamous cell carcinoma to cervical lymph nodes with unknown primary. Patient presents for initial evaluation and treatment planning. A PET CT was ordered using the FDG tracer.

2-5

Female with right frontal scalp lesion. Biopsy positive for T3b melanoma. Presenting for initial staging and treatment planning. A PET CT was ordered using the FDG tracer.

0 / 5 Cases

Worklist 3

3-1

Male recently diagnosed with IgG kappa multiple myeloma, presenting for initial staging. A PET CT was ordered using the FDG tracer.

3-2

Male with history of thyroid cancer. Status post two stage thyroidectomy (2014 and 2020), I-131 ablation. The patient was found to have manubrial, lung and left cervical nodes metastasis, status post resection of manubrium, left neck dissection; wedge resection of right middle lobe metastasis in 2021. Patient is currently on sorafenib. PET/CT performed for restaging. A PET CT was ordered using the FDG tracer.

3-3

Female newly diagnosed with right colon cancer on colonoscopy presenting for staging and initial treatment planning. A PET CT was ordered using the FDG tracer.

3-4

Right breast triple negative poorly differentiated invasive ductal carcinoma, initial staging. A PET CT was ordered using the FDG tracer.

3-5

Stage IIIB (cT3 cN3c M0) left UOQ grade 3, ER negative, PR weak 70%, HER2 + invasive ductal carcinoma of breast, status post 7 cycles TCHP, presenting for treatment response assessment and pre-surgical planning. A PET CT was ordered using the FDG tracer. Submit your report for this study. The patient’s pre-treatment PET CT is also provided for reference.

0 / 5 Cases

Worklist 4

4-1

Male with biopsy proven gastric GIST receiving chemotherapy. A PET CT was ordered using the FDG tracer.

4-2

Female recently diagnosed with right proximal tibial high grade chondroblastic osteosarcoma, presenting for assessment of disease extent for initial staging. A PET CT was ordered using the FDG tracer.

4-3

Central left upper lobe endobronchial mass with pathology revealing low-grade neuroendocrine tumor, favoring carcinoid (typical). Evaluation for initial staging and treatment planning. A PET CT was ordered using the DOTATATE tracer.

4-4

Recently diagnosed primary well differentiated NET within the head of pancreas. Initial evaluation. A PET CT was ordered using the DOTATATE tracer.

4-5

Male with well-differentiated grade 2 metastatic neuroendocrine tumor to the liver, kidney and bladder of unknown primary. Currently treated with octreotide. A PET CT was ordered using the DOTATATE tracer.

0 / 5 Cases

Worklist 5

5-1

Male with T4bNab medullary thyroid cancer status post bronchoscopy with tracheal biopsy and tracheal balloon dilatation presenting for initial staging and treatment planning. A PET CT was ordered using the DOTATATE tracer.

5-2

Male presenting for evaluation of vagal paraganglioma. A PET CT was ordered using the DOTATATE tracer.

5-3

Male with history of T3apN0, Gleason 4+4=8 prostate cancer. The patient has a rising PSA, most recently 0.54. The present study is performed for restaging. A PET CT was ordered using the PSMA tracer.

5-4

Male with history of metastatic castration-sensitive adenocarcinoma of the prostate, status post radical prostatectomy followed by postoperative/salvage radiotherapy completed, presenting with biochemical recurrence for subsequent treatment planning. PSA levels: Most recent 59.18 ng/mL, compared to 14.64 ng/mL A PET CT was ordered using the PSMA tracer.

5-5

Male with history of metastatic hormone sensitive prostate cancer, status post radical prostatectomy, presenting for evaluation for treatment planning. PSA levels: 40.6 ng/mL on 4/6/2022 28 ng/mL on 2/2/2022 25.1 ng/mL on 5/18/2020 A PET CT was ordered using the PSMA tracer.

0 / 1 Unit

Post-Course Activites

Course Evaluation